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A B S T R A C T
Almost 70% of chronic hepatitis C (CHC) patients will have concomitant hepatic steatosis (HS) usually determined
with invasive method. HS serve as negative predictive factor for lower sustained viral response (SVR) in CHC patients
treated with standard of care (SOC) (PEG-IFN and Rib). Retrospective analysis of biochemical, virological and histolo-
gical data in CHC patients treated with PEG-IFN and Ribavarin. Statistical analysis was carried out by Biometrika
Healthcare Research. Level of significance was set to 95% (p<0.05). 72 patients (43 M; 29 F; median age 41y) with CHC
(60 G1; 12 G3) with no concomitant metabolic syndrome were analyzed. HS ranged from 5 to 30% (median 15%). Overall
accuracy of prediction of SVR based on the levels of HS was AUC=0.71 (95% CI=0.58–0.84; p=0.005). When HS was
split regarding cut-off value of 5% significant difference was found between responders and non-responders to treatment
(c2=10.025; df=1; p=0.002). Overall sensitivity was 48% and specificity 91%. Conventional predictive variables (gender,
age, fibrosis and genotype) where combined with HS (>5%) and all together achieved Nagelkerke R squared of 34.0% in
prediction of SVR, with accuracy rate of 75.0%. Further, invasive variables (fibrosis and HS) where replaced with vire-
mia and body mass index (BMI). All noninvasive variables together achieved Nagelkerke R squared of 26.5% in predic-
tion of SVR with 74% accuracy rate of the logistic regression model. Very low HS (<5%) is negative predictor of SVR and
can be replaced with noninvasive variables (gender, age, viremia and BMI) with same accuracy rate of the logistic regres-
sion model.
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Introduction
Chronic hepatitis C virus (HCV) infection is a global
health problem with an estimated prevalence of 2%, rep-
resenting 120 to 130 million people1. Polyethylene glycol
interferon-a (PegIFN-a) combined with ribavirin (RBV)
is the standard of care (SOC) regimen for HCV, except for
patients with HCV genotype 1 where direct-acting anti-
viral drug (DAA), telaprevir or boceprevir, combined with
PegIFN-a and RBV is the SOC. The main factors influ-
encing the efficacy of HCV antiviral treatments are di-
vided into two categories: viral and host-related. The vi-
ral category includes the HCV genotype, baseline viral
load, and virological response during treatment. On the
other hand host category includes age, gender, race,
drinking habits, obesity, degree of liver fibrosis, and
IL28B gene polymorphisms. Some host factors including
age ³40 years old2, insulin resistance3,4, liver cirrhosis5,
metabolic syndrome6,7 and liver steatosis, can serve as a
predictor to poor response to SOC.
Approximately 50% of patients chronically infected
with hepatitis C virus have fatty infiltration of the liver
also referred to as liver steatosis8,9. This complication is
not just associated with the failure of interferon therapy
but also with progression of liver fibrosis10–12. The patho-
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genesis of HCV-related steatosis is likely to be multifac-
torial and three predominant forms have been proposed:
viral, metabolic and alcohol-induced steatosis. In pa-
tients infected with genotype 3, steatosis is mostly vi-
rus-induced and often severe. It has been suggested that
HCV genotype 3 core protein could inhibit very-low-den-
sity lipoprotein (VLDL) secretion and induce liver steato-
sis13. This type of steatosis correlates with high viral load
and resolves after successful antiviral therapy12,14,15. In
contrast, in patients infected with genotypes other then
3, steatosis is mainly linked to obesity and metabolic dis-
orders including peripheral insulin resistance2,6. In these
patients, the steatosis resembles nonalcoholic steato-
-hepatitis, is unrelated to viral load, and does not neces-
sarily improve following successful eradication of HCV16.
The value of steatosis as a negative predictor of re-
sponse to anti-HCV therapy was confirmed in two large
clinical trials. In one study, 574 HCV patients treated
with the SOC were evaluated, and the results showed
that the presence of steatosis reduces the likelihood of
achieving EVR and SVR in genotype-1 infected patients17.
In another study, 231 HCV patients treated with the SOC
were evaluated18. The results showed that steatosis neg-
atively affected SVR in HCV genotype non-3-infected pa-
tients.
The aim of this study was to confirm hepatic steatosis
(HS) as negative predictive factor for lower sustained vi-
ral response (SVR) in cohort of chronic hepatitis C (CHC)
patients treated with SOC.
Subjects and Methods
Subjects
This research was conducted as a retrospective study
which involved one hundred and three CHC patients. All
patients were interferon naive, had positive anti-HCV
and detectable HCV-RNA. Patients were treated with
PegIFN-a and ribavirin in University Hospital Centre
Zagreb in 2011. Treatment duration was adjusted ac-
cording to genotype, 24 weeks for patients infected with
genotype 3 and 48 weeks for patients infected with geno-
type 1. Epidemiological data such as, sex, age, alcohol in-
take, weight, height, BMI and history of smoking and hy-
pertension were collected prior to treatment. BMI was
calculated as the weight divided by the square of height
(kg/m2). All patients underwent liver biopsy prior the
treatment together with laboratory assessment done
within one week prior to biopsy. Baseline laboratory as-
sessment included AST, ALT, GGT, cholesterol and tri-
glycerides.
Assessment of HCV-RNA
HCV-RNA was detected using commercial assay kits:
qualitative PCR test (COBAS Amplicor HCV RNA test,
v2.0, Roche Diagnostic Systems, Branchburg, NJ); viral
load by quantitative RT-PCR test (COBAS Amplicor TM–
HCV Monitor test, v2.0, Roche Diagnostic Systems,
Branchburg, NJ) and genotypes by INNO-LIPA HCV II
(Innogenetics N.V., Ghent, Belgium).
All patients had HCV genotype 1 or 3. Viral load was
determined at baseline, after the 12th week of therapy for
genotype 1 patients and for all patients at the end of
therapy and 6 months after the therapy was stopped.
Definition of virological responses were: 1) end-of-treat-
ment virological response (ETVR) if the HCV RNA was
undetectable at the end of treatment; 2) sustained viro-
logical response (SVR) if the HCV RNA remained unde-
tectable 6 months after cessation the therapy; 3) relapse
= patients who achieved ETVR and become positive af-
ter the therapy was stopped and 4) non-response = pa-
tients who did not achieved ETVR.
Histopathology
A pathological assessment was made on sections from
formalin-fixed and paraffin-embedded liver biopsy stai-
ned with hematoxylin-eosin. All specimens were cen-
trally evaluated by single pathologist. Histological activ-
ity and stage of fibrosis were scored according to Ishak
model19. Hepatic steatosis (HS) was graded as the per-
centage of hepatocytes containing macrovesicular fat drop-
lets: grade 0 (<5%); grade 1 (5–33%); grade 2 (34–66%);
and grade 3 (>66%).
Histology activity index (HAI) was determined by the
combining the scores for portal inflammation, lobular de-
generation and necrosis, and periportal necrosis. The
stage was defined according to the Ishak fibrosis score: 0
= absence; 1 = fibrous expansion of some portal areas;
2= fibrous expansion of most portal areas; 3 = fibrous
expansion of most portal areas with occasional portal to
portal bridging; 4 = fibrous expansion of portal areas
with marked bridging (portal to portal as well as portal
to central); 5 = marked bridging with occasional nodules
(incomplete cirrhosis); 6 = cirrhosis, probable or defi-
nite.
Statistical analysis
Level of significance was set to 95% (p<0.05), and all
confidence intervals were given on the 95% level. In all
instances two-tailed tests of statistical significance were
used. Since sample size was small, normality of continu-
ous variables distributions was tested with Shapiro-Wilk
test. Median and interquartile range were used as mea-
sures of central tendency and variability when the distri-
bution statistically significantly deviated from the nor-
mal one. Statistical significance of differences in catego-
rical variables’ frequencies between groups were analyzed
by Chi-square (c2) test and phi coefficient (j) of associa-
tion was used as the standardized measure of effect size
in case of statistically significant difference. Group dif-
ference in continuous, but not normally distributed vari-
able was analyzed using Mann-Whitney U test. The anal-
yses were carried out using SPSS 17.0 (SPSS Inc., Chica-
go, IL, USA) statistical software package. Confidence in-
tervals for proportions were determined using Statistics
Calculator 3.0 (StatPac Inc., Bloomingtom, MN, USA).




Of 103 retrospectively analyzed CHC patients only 72
of them were included in statistical analysis. Excluded
patients were those with possible signs of metabolic syn-
drome (obesity, hypertension and diabetes mellitus). Me-
dian age was 41 (IQR 29.3–54). Overall SVR was ob-
served in 69.4%. All baseline characteristics for analyzed
patients are summarized in Table 1.
Viral, biochemical and histological features
Majority of patients (58.3%) had high viral load
(>600.000 IU/L). Liver enzymes were normal in minor
patients: ALT in 4 patients; AST in 26 patients and GGT
in 26 of 72 patients. Median level for liver enzymes were:
for ALT 67 IU/L (IQR 48.3–91), AST 40.5 IU/L (IQR
32–56) and for GGT 48 IU/L (IQR 36–76.3). Different ra-
tio between liver enzymes was calculated due to fact that
some of liver enzymes (AST and GGT) are known as
steatotic enzymes. Median AST/ALT ratio was 0.60 (IQR
0.50–0.80) while median GGT/ALT ratio was 0.82 (0.37–
1.16).
Liver histological examination showed that among 72
patients median of liver cylinder size was 2 cm (IQR
1.4–3) with median number of portal spaces of 16 (IQR
14–18) what was good enough to include them in statisti-
cal analysis. Summary of histological findings is showed
in Table 2.
Determination of cut-off values for
hepatocytes steatosis
HS ranged from 5 to 30% (median 15%). Proportion of
patients with different severity of HS was: 48.6% with
grade 0; 19.4% with grade 1; 23.6% with grade 2 and
8.3% with grade 4.
Overall accuracy of prediction of SVR (area under the
ROC curve, Picture 1) based on the levels of hepatocytes
steatosis was AUC=0.71 (95% CI=0.58–0.84; p=0.005).
Area under the curve was statistically significant, mean-
ing that level of hepatocytes steatosis was statistically
significant predictor of sustained virological response.
Youden index calculated as:
J = max {sensitivity + specificity – 1}
where c ranges over all possible hepatocytes steatosis va-
lues, was J=0.39 (95% CI=0.13–0.50) with correspond-
ing value of hepatocytes steatosis = 5%. Youden index
calculator at value of hepatocytes steatosis = 20%, was
0.33 (95% CI=0.06–0.57), and at value of hepatocytes
steatosis = 25%, was 0.37 (95% CI=0.10–0.50). All data
were shown in Table 3.
Relationship of hepatic steatosis and
sustained virological response
Statistically significant difference was found in level
of HS when it was split as £5% and >5% (c2=10.025;
df=1; p=0.002; phi coefficient=0.373); as £20% and >20%
(c2=7.444; df=1; p=0.006; j=0.322); and as £25% and
>25% (c2=9.876; df=1; p=0.002; j=0.370). Participants








Body mass index (median; IQR) 24.2 (22.8–25.8)
Body mass index (N; %)
Normal (<24.9) 43 (59.7)
Overweight (25.0+) 29 (40.3)
Body weight, kg (median; IQR) 73 (66.3–79)







IQR – interquartile range
Fig. 1. ROC levels of hepatocytes steatosis, in prediction if sus-
tained virological response with 95% confidence interval (N=72).
TABLE 2
HISTOLOGICAL FINDING (N=72)
Piecemeal necrosis (median; IQR) 2 (2–3)
Confluent necrosis (median; IQR) 1 (0–3)
Focal necrosis (median; IQR) 2 (2–3)
Portal inflammation (median; IQR) 3 (2–3)
Activity (median; IQR) 8.5 (7–11)
Fibrosis (median; IQR) 4 (3–4.8)
IQR – interquartile range
who have SVR had statistically significantly lower HS
(Mann-Whitney U=864, Z=–1.958; p=0.049; AUC=0.38).
Participants with 21–30% of HS had 0.8 times smaller
odds for achieving SVR (OR=0.2; 95% CI=0.63–0.79),
compared to participants with 0–10% of HS. Also, partici-
pants with HS >5% had 0.9 times smaller odds for
achieving SVR (OR=0.1; 95% CI=0.02–0.51), compared
to participants with HS £5%. Participants with HS >20%
had 0.8 times smaller odds for achieving SVR (OR =0.2;
95% CI=0.08–0.69), compared to participants with HS
£20%. Those with HS >25% had 0.8 times smaller odds
for achieving SVR (OR=0.2; 95% CI=0.06–0.55), com-
pared to participants with HS £25%. Regarding numeric
HS variable, with each unit HS increase odds for achiev-
ing SVR are 0.06 times smaller (OR=0.94; 95% CI=0.90–
0.99) (Table 4).
Relationship of demographic, virological and
histological characteristics with sustained
virological response
When all demographic, virological and histological
variables were entered in the multivariate logistic re-
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TABLE 3
CRITERION VALUES AND COORDINATES OF THE ROC CURVE OF HAPATOCYTES STEATOSIS IN PREDICTION OF SUSTAIND
VIRAL RESPONSE (N=72)
HS Sensitivity Specificity +LR 95% CI –LR 95% CI +PV –PV
<0 0.0 100.0 1.0 1.0–1.0 30.6
£0 10.0 95.5 2.20 0.3–49.6 0.94 0.9–1.2 83.3 38.1
£5 48.0 90.9 5.28 1.5–31.7 0.57 0.5–0.8 92.3 43.5
£10 56.0 68.2 1.76 0.9–4.0 0.65 0.4–1.1 80.0 40.5
£15 60.0 59.1 1.47 0.9–2.9 0.68 0.4–1.2 76.9 39.4
£20 78.0 54.5 1.72 1.1–3.0 0.40 0.2–0.9 79.6 52.2
£25 82.0 54.5 1.80 1.2–3.0 0.33 0.2–0.7 80.4 57.1
£30 94.0 13.6 1.09 0.9–1.3 0.44 0.1–2.6 71.2 50.0
£40 100.0 0.0 1.00 1.0–1.0 69.4
HS – hepatocytes steatosis; LR+ – positive likelihood ratio, ratio between the probability of a lower level of HS given the presence of
the SVR and the probability of a lower level of HS given the absence of SVR; +PV – positive predictive value, probability of SVR if HS
is lower or equal to the given value
TABLE 4
PREDICTION OF SVR REGARDING HS
SVR No SVR
p; effect ORuv 95% CI
N (%) N (%)
Hepatic steatosis
0–10% 28 (80.0) 7 (20.0)
0.058
1.0
11–20% 11 (78.6) 3 (21.4) 0.9 (0.20–4.20)
21–30% 8 (47.1) 9 (52.9) 0.2 (0.63–0.79)
31–40% 3 (50.0) 3 (50.0) 0.3 (0.04–1.52)
Hepatic steatosis
<5% 24 (92.3) 2 (7.7)
0.002; 0.373
1.0
>5% 26 (56.5) 20 (43.5) 0.1 (0.02–0.51)
Hepatic steatosis
<20% 39 (79.6) 10 (20.4)
0.006; 0.322
1.0
>20% 11 (47.8) 12 (52.2) 0.2 (0.08–0.69)
Hepatic steatosis
<25% 41 (80.4) 10 (19.6)
0.002; 0.370
1.0
>25% 9 (42.9) 12 (57.1) 0.2 (0.06–0.55)
Hepatic steatosis* 10 (5–20) 30 (10–10) 0.003; 0.29 0.94 (0.90–0.99)
p – c2-test for nominal variables, Mann-Whitney test for numeric; the level of statistical significance, or probability of type I error (al-
pha); effect – standardized effect size given by statistically significant results; phi coefficient for c2; AUC for Mann-Whitney test; OR –
odds ratio; 95% CI-95% confidence interval for odds ratio; uv – univariate logistic regression; * Median (interquartile range)
gression model, included variables together achieved Na-
gelkerke R squared of 41.6% in prediction of SVR. The
accuracy rate of the logistic regression model was 76.4%,
meaning that 76.4% of participants were correctly classi-
fied as those with or without SVR, by mentioned vari-
ables.
In the next step, HS was added to the model. Firstly,
HS was included as grouped into four categories (0–10%;
11–20%; 21–30%; 31–40%). Secondly, original, numeric
HS was added into the model instead of the grouped one.
Thirdly, HS split by newly determined cut-off values
(£5%) was added into the model; fourthly, HS split by
newly determined cut-off values of 20% was added into
the model, and finally, HS split by newly determined
cut-off values of 25% was added into the model.
When HS (grouped into four categories) was included
into the model, there was no statistically significant en-
hancement to prediction of SVR (c2=2.485; df=3; p=
0.478), although Nagelkerke R squared increased to
45.0%, and accuracy rate increased to 80.6%. When origi-
nal, numeric HS was included into the model, statisti-
cally significant enhancement to prediction of SVR was
found (c2=3.886; df=1; p=0.049). Nagalkerke R squared
increased from 41.6% to 46.9%, and the accuracy rate in-
creased from 76.4% to 83.3%. When HS split by cut-off of
5% was included into the model statistically significant
enhancement to prediction of SVR was found (c2=
11.720; df=1; p=0.001). Nagalkerke R squared increased
from 41.6% to 56.6%, and the accuracy rate increased
from 76.4% to 83.3%. When HS split by cut-off of 20%
was included into the model, there was no statistically
significant enhancement to prediction of SVR (c2=2.375;
df=1; p=0.123), although Nagalkerke R squared increa-
sed from 41.6% to 44.9%, and the accuracy rate increased
from 76.4% to 79.2%. Finally, HS split as £25% and >25%
was included into the model, statistically significant en-
hancement to prediction of SVR was found (c2=4.784;
df=1; p=0.029). Nagalkerke R squared increased from
41.6% to 48.0%, and the accuracy rate increased from
76.4% to 81.9%.
Discussion
The findings in the current study evaluating steatosis
in 72 chronic hepatitis C patients represent the single
center cohort study. Whilst retrospective, this study ex-
plored the relationships between steatosis and possibility
to achieve sustained viral response among patients with
chronic hepatitis C infected with genotype 1 and 3.
Hepatic steatosis was graded as the percentage of hepa-
tocytes containing macrovesicular fat droplets. Majority
of our patients had 5% or less hepatocytes affected with
steatosis. Interestingly, when hepatic steatosis was split
at the cut-off value of 5%, significant difference was
found between responders and non-responders to treat-
ment. Area under the curve was statistically significant,
meaning that level of hepatocytes steatosis was statisti-
cally significant predictor of sustained virological re-
sponse.
Steatosis has been identified as a negative predictor
factor of response to antiviral therapy in many studies
and still controversies exists. Steatosis appears to have a
greater clinical impact on patients with genotype 1 infec-
tion where it decreases sustained response rates and is
associated with fibrosis. The mechanism is not com-
pletely understood. In contrast, hepatitis c virus geno-
type 3 has been shown to be more sensitive to inter-
feron-based therapy perhaps related to its unique inter-
action with host lipid metabolism. Some authors propose
that interventions aiming at reducing hepatic steatosis
prior to the onset of antiviral therapy may be of benefit
to patients infected with genotype 1.
Problem with hepatic steatosis is in fact that is main-
ly confirmed by invasive method in majority of countries.
Among clinicians tendency to find non-invasive and spe-
cific method of evaluating hepatic steatosis should be pri-
ority. Available radiographic methods are mainly opera-
tor dependent.
In conclusion we can say that steatosis induced by
HCV infection has been confirmed as crucial factor that
influence the outcome of antiviral treatments. Having in
mind that some countries, like Croatia, still have pegy-
lated interferon and ribavirin as standard of care in first
line treatment, patients with high percentage of hepatic
steatosis should be excluded from that treatment algo-
rithm. Noninvasive methods for determination of hepa-
tic steatosis or combination of laboratory parameters
that can replace degree of hepatic steatosis are needed.
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STEATOZA JETRE ZAMIJENJENA NEINVAZIVNIM PARAMETRIMA DOMA]INA I VIRUSA
MO@E POSLU@ITI KAO NEGATIVNI PREDIKTIVNI MODEL U PACIJENTA S KRONI^NIM
HEPATITISOM C
S A @ E T A K
Gotovo 70% bolesnika s kroni~nim hepatitisom C (KHC) imat }e prate}u steatozu jetre (SJ) uglavnom utvr|enu
invazivnom metodom. SJ slu`i kao negativni prediktivni ~imbenik za sni`eni trajni virolo{ki odgovor (SVR, eng. sus-
tained viral responce) u bolesnika s KHC lije~enih standardnom terapijom (PEG IFN-a i Rib). Statisti~ka analiza pro-
vedena je u Biometrika Healthcare Research. Razina statisti~ke zna~ajnosti odre|ena je na 95% (p<0,05). Analizirano
je 72 bolesnika (43 M; 29 @; medijan starosti 41 g) s KHC (60 G1; 12 G3) bez prate}eg MS (metaboli~kog sindroma).
Raspon SJ bio je od 5 do 30% (medijan 15%). Sveukupna to~nost predikcije SVR na temelju razine SJ bila je AUC=0,71
(95% CI=0,58–0,84; p=0,005). Podijeliv{i SJ s obzirom na grani~nu vrijednost od 5% na|ena je zna~ajna razlika izme|u
bolesnika koji su odgovorili na terapiju i onih koji nisu (c2=10,025; df=1; p=0,002). Sveukupna osjetljivost bila je 48% i
specifi~nost 91%. Uobi~ajene prediktivne varijable (spol, dob, fibroza i genotip) bile su kombinirane sa SJ (>5%) te su
zajedni~ki dosegnuli Nagelkerke R squared od 34,0% u predvi|anju SVR s razinom to~nosti od 75,0%. Nadalje, inva-
zivne varijable (fibroza i SJ) bile su zamijenjene s viremijom i indeksom tjelesne mase (BMI, eng. body mass index). Sve
neinvazivne varijable postigle su zajedni~ki Nagelkerke R squared od 26,5% u predvi|anju SVR s razinom to~nosti od
74% prema modelu logisti~ke regresije. Jako niska SJ (<5%) je negativan pretkaziva~ (prediktor) SVR i mo`e biti
zamijenjena s neinvazivnim varijablama (spol, dob, viremija i BMI) iste razine to~nosti prema modelu logisti~ke regre-
sije.
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